webinars.endpts.com Open in urlscan Pro
54.185.102.17  Public Scan

Form analysis
0 forms found in the DOM

Text Content

 * Endpoints News
 * watch now

webinar recording available - register to watch


KEEPING PACE WITH THE EVOLVING GLOBAL LANDSCAPE IN VACCINE DEVELOPMENT

Hear from a panel of Life Science experts on the latest advancements and
innovative modalities paving the way in the global vaccine development space.
What has been COVID-19’s impact on drug development and the regulatory
landscape? Key factors contributing to Asia Pacific being recognised as the hub
for vaccine development and opportunities for biotech’s to leverage. Key
considerations for pre-clinical and clinical planning to accelerate vaccine
development, supporting a robust global strategy.

SPONSORED BY
SHARE ON

watch now
watch the webinar
First name
Last name
Email
Company
Job Title
Country --select--AfghanistanÅland IslandsAlbaniaAlgeriaAmerican
SamoaAndorraAngolaAnguillaAntarcticaAntigua and
BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBonaire,
Sint Eustatius and SabaBosnia and HerzegovinaBotswanaBouvet IslandBrazilBritish
Indian Ocean TerritoryBrunei DarussalamBulgariaBurkina FasoBurundiCabo
VerdeCambodiaCameroonCanadaCayman IslandsCentral African
RepublicChadChileChinaChristmas IslandCocos (Keeling)
IslandsColombiaComorosCongoCongoCook IslandsCosta RicaCôte
d'IvoireCroatiaCuraçaoCyprusCzechiaDenmarkDjiboutiDominicaDominican
RepublicEcuadorEgyptEl SalvadorEquatorial
GuineaEritreaEstoniaEswatiniEthiopiaFalkland Islands (Malvinas)Faroe
IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern
TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard
Island and McDonald IslandsHoly SeeHondurasHong Kong
SARHungaryIcelandIndiaIndonesiaIraqIrelandIsle of
ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKoreaKuwaitKyrgyzstanLao
People's Democratic
RepublicLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacau
SARMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall
IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew
CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorthern Mariana
IslandsNorth MacedoniaNorwayOmanPakistanPalauPalestinePanamaPapua New
GuineaParaguayPeruPhilippinesPitcairnPolandPortugalPuerto
RicoQatarRéunionRomaniaRussian FederationRwandaSaint BarthélemySaint Helena,
Ascension and Tristan da CunhaSaint Kitts and NevisSaint LuciaSaint Martin
(French part)Saint Pierre and MiquelonSaint Vincent and the GrenadinesSamoaSan
MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra
LeoneSingaporeSint Maarten (Dutch part)SlovakiaSloveniaSolomon
IslandsSomaliaSouth AfricaSouth Georgia and the South Sandwich IslandsSouth
SudanSpainSri LankaSurinameSvalbard and Jan
MayenSwedenSwitzerlandTaiwanTajikistanTanzaniaThailandTimor-LesteTogoTokelauTongaTrinidad
and TobagoTunisiaTurkeyTurkmenistanTurks and Caicos
IslandsTuvaluUgandaUkraineUnited Arab EmiratesUnited KingdomUnited States Minor
Outlying IslandsUnited States of AmericaUruguayUzbekistanVanuatuVenezuelaViet
NamVirgin Islands (British)Virgin Islands (U.S.)Wallis and FutunaWestern
SaharaYemenZambiaZimbabweOther
register to watch

No cost to register, subject to confirmation

By registering for this event, you accept that you may receive direct
communication from the sponsor(s).

If you are experiencing problems with your registration, please try the Zoom
registration page.


SUSHANT SAHASTRABUDDHE

ASSOCIATE DIRECTOR GENERAL, INTERNATIONAL VACCINE INSTITUTE (IVI)

Dr. Sushant Sahastrabuddhe, Associate Director General at the International
Vaccine Institute (IVI), joined in July 2010, leading the clinical trials of
IVI’s typhoid vaccine and process to achieve its licensure, the global clinical
development of and licensure of SK bioscience’s COVID-19 vaccines and Phase 1
and 2 trials of Bharat Biotech’s Chikungunya vaccine. As a vaccine enthusiast
with more than 17 years of experience in multiple countries across diverse
projects, he continues to lead collaborative efforts with companies and partners
in Korea, India and globally to get these vaccines through early- to late-stages
of their clinical development. Dr. Sahastrabuddhe is also the Associate Editor
for Vaccines for tropical diseases and associated with Yonsei University as
Research Professor and with Universite Claude Bernanrd, Lyon France as Research
Fellow. In 2021, Dr. Sahastrabuddhe was named an ‘Honorary Citizen of Seoul’ for
his contributions to the joint efforts with Korean companies and international
partners to develop vaccines against COVID-19 and other diseases.


PAUL GRIFFIN

ASSOCIATE PROFESSOR, INFECTIOUS DISEASES PHYSICIAN, MICROBIOLOGIST, UNIVERSITY
OF QUEENSLAND

An Infectious Diseases Physician and Microbiologist, Dr. Paul Griffin was
appointed as the Director of Infectious Diseases at Mater Health Services in
2013 and continues an appointment as an Associate Professor of Medicine at the
University of Queensland Medical School. Additionally, Dr. Griffin chairs the
Advanced Training Committee in Infectious Diseases with the Royal Australasian
College of Physicians, the committee that oversees the training of Infectious
Diseases specialists in Australia. Previously, Dr. Griffin was the Principal
Investigator (PI) and Medical Director at Nucleus Network, a contract research
organization specializing in infectious diseases trials, which included a PI
role on in excess of 125 clinical trials predominantly in Infectious Diseases
including novel vaccines and COVID-19 vaccines. With fellowships in Infectious
Diseases from the Royal Australasian College of Physicians, in Clinical
Microbiology from the Royal College of Pathologists of Australasia and from the
Australasian College of Tropical Medicine, Dr. Griffin has an active interest in
vaccine education and advocacy and has become a trusted media authority and
spokesperson across the nation during the COVID-19 pandemic.


JENNIFER ARELLANO

DIRECTOR OF CLINICAL SERVICES (PHILIPPINES), NOVOTECH

Jennifer Arellano is the Director of Clinical Services in the Philippines with
over 25 years of technical and leadership experience in managing clinical trial
operations for sponsors and CROs. With a Bachelor of Industrial Pharmacy from
the University of the Philippines and a Pharmacist license, Jennifer’s research
operations experience includes monitoring, auditing, project leadership,
feasibility, study start-up, driving inspection readiness and hosting regulatory
inspection, client engagement and business development, learning & development
and organization SOP development/review. Jennifer has contributed to the
transformation of the Philippine clinical research industry – bringing
improvement to the local clinical research regulations and practices and is the
founding President of a non-profit organization, the Philippine Clinical
Research Professionals Inc, with more than 400 members from pharmaceutical and
CROs and has. More recently, volunteered pro-bono services during the Covid-19
pandemic to provide trial management consultancy to the Philippine DOH-funded
trials such as WHO Solidarity COVID-19 Treatment and Vaccine trials, Avigan
COVID-19 treatment trial, and Philippine Heart Association funded cardiovascular
outcome study.


BABAJI YADAV

SENIOR CONSULTANT, NOVOTECH DRUG DEVELOPMENT CONSULTING

Babaji Yadav is a Senior Consultant with over eight years of academic experience
in pre-clinical oncology drug development and eight years of industry experience
in drug development. Babaji has a strong background in pharmaceutical sciences
with a Ph.D. in Pharmacology and Toxicology from the University of Otago, New
Zealand. Previously he has worked as a Research Project Manager to oversee
IND-enabling toxicology studies for lead oncology drugs and, prior to joining
Novotech, was a Clinical Project Manager for early-phase oncology trials. Babaji
is a UK Registered Toxicologist and at Novotech he is focused on providing
technical toxicology advice and product development strategies to facilitate the
entry of client’s compounds into clinical trials. Babaji has experience in small
molecules, combination products, and biologicals including vaccines, proteins,
monoclonal antibodies, and advanced cell and gene therapies.

MODERATOR


KARI ABITBOL

DIRECTOR, CLIENT SUCCESS, ENDPOINTS NEWS

As head of the client success team at Endpoints News, Kari oversees campaign
delivery for all advertising and client-directed webinars.

close


YOUR SEAT IS RESERVED!


KEEPING PACE WITH THE EVOLVING GLOBAL LANDSCAPE IN VACCINE DEVELOPMENT

11:00 am - 12:00 pm EST
16:00 - 17:00 LOCAL TIME

A confirmation email with information on how to join the webinar has been sent
to you.

Before joining, be sure to check system requirements to avoid any connection
issues.

close


REGISTRATION DECLINED


KEEPING PACE WITH THE EVOLVING GLOBAL LANDSCAPE IN VACCINE DEVELOPMENT

Apologies, the sponsor for this webinar has opted to block certain domains.

Please feel free to check out our other upcoming webinars at
https://webinars.endpts.com/